NEW YORK, Sept 29 (Reuters) - Eli Lilly & Co. (LLY.N: Quote, Profile, Research) said on Friday it had halted a mid-stage human trial of its experimental drug LY674 to slow progression of atherosclerosis after fatty liver deposits were seen in a trial of primates receiving the same compound.
